ORKA Company Profile and Key Details

NASDAQ : ORKA

Oruka Therapeutics

$35.28

-0.28-0.79%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Oruka Therapeutics, Inc. (ORKA) stock declined over -0.79%, trading at $35.28 on NASDAQ, down from the previous close of $35.56. The stock opened at $35.61, fluctuating between $34.78 and $36.53 in the recent session.

Stock Snapshot

35.56

Prev. Close

1.32B

Market Cap

34.78

Day Low

N/A

P/E Ratio

N/A

EPS (TTM)

N/A

Cash Flow per Share

35.61

Open

37.45M

Number of Shares

36.53

Day High

81.94%

Free Float in %

N/A

Book Value

325.39K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 25, 2026	35.61	36.53	34.78	35.28	333.39K
Feb 24, 2026	33.49	36.29	33.49	35.56	432.87K
Feb 23, 2026	32.49	33.99	32.22	33.32	240.45K
Feb 20, 2026	32.25	32.96	31.15	32.34	394.67K
Feb 19, 2026	32.07	32.80	31.08	32.42	375.4K
Feb 18, 2026	32.65	33.69	31.98	32.27	195.38K
Feb 17, 2026	32.01	33.19	31.65	32.68	260.66K
Feb 13, 2026	32.81	33.96	31.95	32.21	187.04K
Feb 12, 2026	32.70	33.63	31.50	32.64	467.75K
Feb 11, 2026	32.95	32.98	31.00	32.21	490.79K
Feb 10, 2026	33.26	33.84	32.51	32.88	206.83K
Feb 09, 2026	33.89	33.89	32.47	33.26	173.91K
Feb 06, 2026	32.03	33.43	31.38	33.05	495.84K
Feb 05, 2026	32.84	34.13	31.15	31.42	345.65K
Feb 04, 2026	34.82	34.82	32.49	33.00	259.63K
Feb 03, 2026	34.60	35.16	33.25	34.55	384.33K
Feb 02, 2026	34.28	35.46	33.58	34.30	482.76K
Jan 30, 2026	34.70	35.45	32.93	34.23	370.18K
Jan 29, 2026	35.24	36.06	34.48	35.26	346.25K
Jan 28, 2026	35.23	35.58	33.84	35.16	561.43K

Contact Details

Menlo Park, MA

United States

http://www.orukatx.com 203 554 7604

About Company

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Stock Peers

ARGX

-23.33-2.78%

argenx SE$816.95 REGN

12.09+1.57%

Regeneron Pharmaceuticals, Inc.$784.28 UTHR

61.67+13.03%

United Therapeutics Corporation$535.10 VRTX

-4.38-0.90%

Vertex Pharmaceuticals Incorporated$483.05 MDGL

-4.99-1.13%

Madrigal Pharmaceuticals, Inc.$435.01 PRAX

4.84+1.41%

Praxis Precision Medicines, Inc.$347.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.49-1.65%

Alnylam Pharmaceuticals, Inc.$327.36 KRYS

5.6+2.10%

Krystal Biotech, Inc.$272.50 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Oruka Therapeutics, Inc. (NASDAQ:ORKA) closed at $35.28 USD, losing -$0.28 (-0.79%) from the previous close of $35.56. The stock is currently within 5% of its 52-week high $5.49 and $36.53. With a market capitalization of about $1.32 billion, Oruka Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.44). Key stats such as the average daily volume over the past year has been around 530.59 thousand shares, volume is running light vs its 52-week average. Headquartered in Menlo Park, MA, Oruka Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Lawrence Otto Klein, the company employs approximately 28 people and listed since August 08, 1997. Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications.

Technical Performance

ORKA has shown sold momentum, gaining 8.28% over the past week and 20.92% over the past quarter, though year-to-date performance is up 9.63%. Short-term trend indicators are bearishly aligned (SMA20 5.62%, SMA50 10.67%, SMA200 63.03%). The stock’s 14-day RSI is 62.04 (firm momentum), while the ATR of 1.97 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.37% below its high and over 543.21% above its low. Average 10-day trading volume of 318.97 thousand shares is below the 3-month average of 505.25 thousand, indicating normal recent market interest.

Valuation Metrics

Oruka Therapeutics, Inc. trades at a P/E ratio of -14.15, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.18 trading at moderately above to book value. The P/FCF stands at -15.53, also below market averages.

Dividend & Fair Value

Oruka Therapeutics, Inc. last paid a dividend of 19.36 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.61. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Oruka Therapeutics, Inc. generated EPS of -$2.42 over the past year. Five-year average earnings growth is 36.88%. Wall Street analysts project EPS growth of 9.89% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $75.00 to $40.00. The high target offers 112.59% upside. The low target suggests 13.38% downside. The mean target is $53.36. This offers 51.25% upside. Oruka Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -1.79%. The prior quarter beat by -4.17%. Over the last six quarters, Apple has recorded several small beats. These include 200.0% in November 06, 2024.

Shareholding & Insider Activity

Oruka Therapeutics, Inc. has 37.45 million shares outstanding. The public float is 22.41 million shares, elevated short interest at 14.37% of float. This equals 3.36 million shares. The short ratio is 19.35 days. Institutional investors hold 96.9% of the float. Insiders own 3.82%. Venrock Healthcare Capital Partners III, L.P. holds 4.15 million shares, Sandler Laura Lee has 205.08 thousand shares and Goncalves Joana has 34.02 thousand shares. Over the past six months, insider transactions show net selling. They sold 7.74 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Oruka Therapeutics has not generated any revenue.
On valuation metrics, Oruka Therapeutics trades at a P/E of -14.15, P/S of 0.00 and P/B of 3.18. The current ratio is 16.94 and quick ratio is 16.94. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -44.16.

Price Forecast & Outlook

Our AI price prediction model suggests that Oruka Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.0%, with price expected at $34.22 by March 11, 2026, within a range of $32.89 to $35.64 3-Month Outlook: Projected rise of 39.77%, reaching $49.31 by May 25, 2026, with a range of $43.77 to $54.63. 1-Year Outlook: Projected gain of 0.51%, with price at $35.46 by February 25, 2027, within a range of $32.57 to $39.11.

Key Takeaways

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares are flat 9.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Oruka Therapeutics, Inc. trading at a premium to the broader market with a P/E of -14.15. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $48.74, suggesting 38.15% upside. Our AI forecast model points to short-term weakness (-3.0% over two weeks), a medium-term rise (39.77% over three months), and a longer-term gain (0.51% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Oruka Therapeutics, Inc. (ORKA) stock price?

Oruka Therapeutics, Inc. (NASDAQ: ORKA) stock price is $35.28 in the last trading session. During the trading session, ORKA stock reached the peak price of $36.53 while $34.78 was the lowest point it dropped to. The percentage change in ORKA stock occurred in the recent session was -0.79% while the dollar amount for the price change in ORKA stock was - $0.28.

ORKA's industry and sector of operation?

The NASDAQ listed ORKA is part of Biotechnology industry that operates in the broader Healthcare sector. Oruka Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ORKA?

No Data

How ORKA did perform over past 52-week?

ORKA's closing price is 542.62% higher than its 52-week low of $5.49 where as its distance from 52-week high of $36.53 is -3.42%.

How many employees does ORKA have?

Number of ORKA employees currently stands at 28.

Link for ORKA official website?

Official Website of ORKA is: http://www.orukatx.com

How do I contact ORKA?

ORKA could be contacted at phone 203 554 7604 and can also be accessed through its website. ORKA operates from 221 Crescent Street Building 23, Suite 105, Menlo Park, MA , United States.

How many shares of ORKA are traded daily?

ORKA stock volume for the day was 325.39K shares. The average number of ORKA shares traded daily for last 3 months was 530.59K.

What is the market cap of ORKA currently?

The market value of ORKA currently stands at $1.32B with its latest stock price at $35.28 and 37.45M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	28
Beta	-0.44
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

ORKA Company Profile and Key Details

Oruka Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics